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leading to the depletion of intracellular lipid stores. By using agents which target concurrently distinct
adaptive responses to tamoxifen-mediated metabolic reprogramming, we demonstrate increased cytotoxicity.
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ABSTRACT 
 
TAMOXIFEN MEDIATED METABOLIC STRESS: MOLECULAR MECHANISM AND 
THERAPEUTIC OPPERTUNITIES 
Natalie A. Daurio 
Constantinos Koumenis 
Tamoxifen is the most widely used adjuvant chemotherapeutic for the treatment of 
estrogen receptor (ER) positive breast cancer, yet a large body of clinical and preclinical 
data indicates that tamoxifen can modulate multiple cellular processes independently of 
ER status. Here, we describe the ER-independent effects of tamoxifen on tumor 
metabolism. Using combined pharmacological and genetic knockout approaches, we 
demonstrate that tamoxifen inhibits oxygen consumption via inhibition of mitochondrial 
complex I, resulting in an increase in the AMP/ATP ratio and activation of the AMPK 
signaling pathway in vitro and in vivo. We also show that tamoxifen-induced cytotoxicity 
is modulated by isoform-specific effects of AMPK signaling, in which AMPKα1 promotes 
cell death through inhibition of the mTOR pathway and translation. Tamoxifen treatment 
also reprograms cellular metabolism by promoting glycolysis, and altering fatty acid 
metabolism, leading to the depletion of intracellular lipid stores. By using agents which 
target concurrently distinct adaptive responses to tamoxifen-mediated metabolic 
reprogramming, we demonstrate increased cytotoxicity. Tamoxifen synergizes with 
glycolytic inhibitors to kill breast cancer cells and can preferentially kill oxidative 
phosphorylation-dependent populations.  Our results demonstrate novel metabolic 
perturbations by tamoxifen in tumor cells which can be exploited to expand the 
therapeutic potential of tamoxifen treatment beyond ER+ breast cancer.  
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CHAPTER 1: GENERAL INTRODUCTION 
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Breast cancer (BC) is responsible for 1.1 million cancer diagnoses annually world 
wide and 410,000 deaths1. It is second leading cause of cancer related deaths in women 
in the United States. Breast cancer deaths are not the result of the primary tumor but of 
recurrent and metastatic disease. Approximately 10-15% of patients will develop 
metastatic disease in the first 3 years following diagnosis however, the development of 
metastatic lesions after 10 years or more following treatment of the primary tumor is not 
unusual2. Therefore breast cancer patients remain at risk for metastatic disease for their 
entire life.  
Breast cancer is a highly heterogeneous disease with distinct histopathological 
and molecular features that impact disease treatment and prognosis. As a result, a 
classification system with distinct BC subtypes is used to guide clinical decision making 
in combination with traditional variables such as tumor size, invasiveness, and node 
involvement. While scientific reports propose multiple different classification schemes, 
BC can be divided into three categories: luminal BC, which usually express estrogen 
receptor (ER) and/or progesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER2) overexpressing BC, and basal BC. Basal BC is also known as triple 
negative BC referencing the lack of significant ER, PR, or HER2 expression and is the 
most heterogeneous subtype. Triple negative BC is also the most aggressive disease 
and is without any standard targeted therapy options.3  
Tamoxifen is the most widely used non-steroidal selective estrogen receptor 
modulator (SERM) for adjuvant therapy of estrogen receptor-positive (ER+) breast 
cancer (BC).  SERMs are unique in that they exert ER agonist or antagonist properties in 
a tissue specific manner. Originally designed as a contraceptive, then used as a fertility 
agent, tamoxifen has been in the clinic since 1966.  Patients on standard treatment 
receive tamoxifen at 20 mg/day for 5 years with initiation during, or shortly after, surgical 
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removal of the primary tumor and treatment with ionizing radiation or cytotoxic 
chemotherapy. Tamoxifen therapy has reduced disease recurrence by half and overall 
mortality by one-third in ER+ BC patients4. As an anti-cancer agent tamoxifen has a 
relatively safe toxicity profile with the most common side effects including hot flashes 
and irregular menses. Due to its SERM effects, Tamoxifen treatment is also linked to an 
increased risk for endometrial cancer and rare thromboembolic events.  However other 
positive effects have been reported such as an increase in bone mineral density in post-
menopausal women as well as a decrease in total cholesterol and LDL levels that may 
contribute to a decrease in cardiovascular events that are seen in treated populations4. 
The development of tamoxifen resistance remains a significant clinical problem.  
Approximately one-third of women treated with tamoxifen will develop recurrent disease. 
Tamoxifen resistant tumors can be treated with second-generation anti-estrogenic 
therapies but total endocrine resistance often emerges. Only about 15% of these 
tamoxifen-resistant cases will lose ER expression. Additional mechanisms for the 
emergence of resistance are not well understood but have been reported to include 
changes in receptor post-translational modifications, altered downstream signal 
transduction, cross-talk with other growth receptors, and changes in expression of co-
activators and other transcription factors5.  
The anti-tumor effects of tamoxifen are attributed primarily to its antiproliferative 
activity via competitive inhibition of the ER in breast tissue6. Several studies have 
previously described non-ER dependent effects of tamoxifen such as the inhibition of 
protein kinase C (PKC)7–9 and the sensitization of ER-negative tumors to 
chemotherapeutic agents10–12. Furthermore,  during the past two decades, over 25 
clinical trials have been published reporting the effects of “high dose” tamoxifen (i.e. 
doses above those needed to inhibit tumor cell ER activity) ranging from 80 to 720 
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mg/day12 to treat non-breast cancers including glioma13–16, melanoma17,18 and others19,20, 
as a single agent or in combination with chemotherapeutics. While these Phase I and II 
trials showed variable clinical benefit, they clearly demonstrated the safety of high dose 
tamoxifen in diverse patient populations. Pharmacodynamic analyses indicated that  
tamoxifen could reach plasma concentrations  as high as 8 µM19 and additional 
preclinical studies indicated that tamoxifen accumulates in tumor tissue at 60-70 times 
the plasma concentration21.  Therefore, further studies on “high dose” tamoxifen are 
clinically relevant and may result in expanded indications for this affordable and well-
tolerated chemotherapeutic.  
The chemical properties of tamoxifen as a lipophilic weak base contribute to its 
high partition into lipid bilayers and tamoxifen has been previously described to have 
inhibitory effects on mitochondrial  respiratory rate22 and membrane potential23. Agents 
targeting metabolic processes are of particular interest for cancer therapies due to the 
unique metabolic phenotype exhibited by tumors. As rapidly proliferating masses of 
cells, tumors require large pools of macromolecules  to generate the proteins, lipids, and 
nucleotide content necessary to divide as well as sufficient quantities of ATP and 
reducing equivalents to power these processes24. In 1926, Otto Warburg first described 
the preference of cancer cells for converting glucose to lactate via glycolysis, even under 
sufficient oxygenation, an effect that is known as The Warburg Effect, or “aerobic 
glycolysis”25. He hypothesized that this occurs due to defects in cancer mitochondria, 
leaving cancer cells dependent on glycolysis for ATP production. However, more recent 
research has shown that cancer mitochondria are quite functional and has suggested 
that this elevation in glycolysis results from the need for precursor molecules from 
glycolytic intermediates for synthesis of fatty acids, nucleotides and amino acids. 
Tricarboxylic acid (TCA) cycle intermediates can also be used as carbon sources for 
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biosynthetic pathways26. Elevated glutamine uptake seen in cancer also contributes 
carbons to these synthetic pathways necessary for rapid cell division24.  
Metabolic processes are highly regulated and to achieve the phenotype 
necessary for rapid proliferation tumor promotion by certain oncogenes alter the 
metabolic characteristics of cells as a requirement for transformation 27.  Oncogenes 
including myc, nuclear factor-κB (NF- κB), AKT, various tyrosine kinase growth factor 
receptors, Ras, phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of 
rapamycin (mTOR) pathways, and hypoxia- induced factors (HIFs) all enhance 
transcription of factors that promote glycolysis and glutaminolysis. Myc activation also 
promotes an increased rate of protein synthesis. Additionally, changes in metabolic 
enzymes themselves also play a role in tumor promotion including mutations in isocitrate 
dehydrogenase 1 (IDH1), succinate dehydrogenase and fumarase28. Tumor suppressors 
such as p53 and PTEN also play a role in metabolic transformation. Mutations or loss of 
expression of these genes have been shown to promote the aerobic glycolysis 
phenotype29. 
The cancer metabolic phenotype is essential for the survival and growth of 
tumors, making these pathways appealing therapeutic targets. Antimetabolites were the 
first successful cancer therapies to halt tumor growth by interfering with the ability to 
synthesize required molecules. DNA replication was targeted with small molecules 
analogs of essential purine and pyrimidine metabolites including methotrexate, 5-
fluoruracil, and gemcitabine30. Many therapeutic strategies have also been employed to 
target the dependence of cancer on glycolysis, including use of glucose analogs such as 
2-deoxy-glucose (2-DG) and inhibition of glycolysis enzymes including hexokinase II 
(HK2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and phosphofructokinase 
(PFK), as well as blocking the export of lactate, and use of carbohydrate restricted 
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diets31. Amino acid metabolism has been another focus of drug development efforts. 
Inhibition of glutamine uptake and metabolism has shown some preclinical promise and 
L-aspariginase has been used clinically as a successful treatment for leukemia. 
Significant effort has also been directed towards developing inhibitors of fatty acid 
synthesis enzymes including fatty acid synthase (FASN), ATP citrate lyase (ACLY), and 
acetyl-CoA carboxylase (ACC). The success of these therapies targeting metabolic 
pathways have been limited by normal tissue toxicity as well as by metabolic plasticity or 
metabolic pathway redundancy that allows cells to overcome a blockade by upregulation 
of compensatory pathways27,32. As a result, combination therapies targeting multiple 
arms of metabolic pathways or the combination of a metabolic therapy with a cytotoxic 
chemotherapeutic are likely to be more successful.  
Targeting of oncogenes that promote the cancer metabolic phenotype is another 
area of drug discovery research that has gained momentum in recent years. The term 
“oncogene addiction” describes tumor dependence on specific oncogene signaling 
pathways for continued tumor maintenance and progression. In these cases, deprivation 
of oncogene signaling results in tumor regression, therefore, these genes are the focus 
of targeted therapeutic development. Many of these oncogenes contribute to the cancer 
metabolic phenotype and pathway blockade often results in significant metabolic 
alterations. Targeting of mutant BRAF in melanoma and KRAS in pancreatic cancer, 
results in a reversal of the Warburg effect.  Inhibition of PI3K, AKT, and mTOR has long 
been of interest due to their role in cell proliferation. Blockade of these pathways have 
been reported to result in both inhibition of glycolysis as well as oxidative 
phosphorylation33,34. The combination of these oncogene-targeted therapies with 
inhibitors of compensatory metabolic pathways may also increase efficacy and prevent 
resistance. 
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While upregulation of glycolytic and biosynthetic metabolic pathways plays an 
essential role in tumor progression, the function of mitochondrial respiration in cancer 
biology should not be discounted. Oxidative phosphorylation has been reported to 
provide 25-60% of the ATP pools for cancer cells and substrate availability has been 
shown to regulate oxidative capacity. Therefore, at times of glucose deprivation, 
mitochondria respiration may increase to maintain cellular function and the use of 
glutamine as a carbon source requires mitochondrial oxidative capacity35.   Electron 
transport also functions to regenerate nicotinamide adenine dinucleotide (NAD+) and 
flavin adenine dinucleotide (FAD)35. Moreover, TCA cycle intermediates are required for 
synthesis of amino acids and nucleotides from both glucose and glutamine. Oxidative 
phosphorylation (OXPHOS) regeneration of reducing equivalents is necessary for 
continued TCA cycle activity36.  Cancer heterogeneity also highlights the importance of 
mitochondrial metabolism in cancer. Cancer stem cells and tumor initiating cells have 
been showed to have higher levels of OXPHOS37,38. Respiration has also been shown to 
support the extravasation and intravasation processes required for metastasis39.  
Moreover, aggressive and drug resistant populations also characteristically have 
increased levels of OXPHOS38,40. Dormant cancer cells also may also depend on 
respiration to survive nutrient depleted conditions, allowing for cancer recurrence37,41.  
Since mitochondrial oxidative phosphorylation plays a significant role in cancer 
promotion, pharmacological inhibition of respiration may be an important drug target for 
the advancement of therapeutic options. Evidence from current literature supports the 
efficacy of this strategy. Metformin targeting of complex I of the electron transport chain 
has been shown to reduce tumorigenesis42. Resistance to targeted therapies in BRAF 
and KRAS driven tumors limits the therapeutic options in cancers such as melanoma 
and pancreatic cancer. The drug resistant populations are thus dependent on elevated 
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OXPHOS and drugs that target mitochondrial metabolism, such as biguanides,  have 
potential utility in targeting such resistant populations by synthetic-lethality approaches 
38,40,43–45. Moreover, tumor hypoxia is a significant obstacle to the clinical success of 
ionizing radiation and other DNA damaging agents. Inhibition of mitochondrial respiration 
has been validated as a strategy to reduce tumor hypoxia and sensitize tumors to these 
therapies46.   
One of the consequences of OXPHOS inhibition, especially in metabolically 
active cancer cells, is the activation of the AMP-activated protein kinase (AMPK), the 
major regulator of cellular energy homeostasis. AMPK is activated when the AMP:ATP 
ratio increases, signaling a loss in cellular energy charge. Once activated, AMPK 
restores cellular energy levels by promoting catabolic and inhibiting anabolic 
processes47. AMPK is universally expressed across all eukaryotes as a heterotrimeric 
protein composed of an alpha catalytic subunit, and beta and gamma regulatory 
subunits. The gamma subunit contains four surface adenyl binding sites containing 
tandem repeats known as CBS repeats. Mammalian AMPK has a constitutively bound 
AMP at site 4 while site 2 remains unoccupied. AMP and ATP compete for binding at 
sites 1 and 348–50. Interestingly, expression of adenylate kinase maintains the reaction 
2ADP↔AMP+ATP at equilibrium. Therefore any loss in cellular energy levels will result 
in an increase in both AMP and ADP. However, since intracellular AMP pools are much 
smaller than ADP pools, their relative increase will be more significant making it logical 
that AMPK is most sensitive to the AMP/ATP ratio. When AMP binds these sites, a 
conformational change is induced that prevents the dephosphorylation of the catalytic 
alpha subunit of AMPK by phosphatases and enhances phosphorylation by upstream 
kinases. More specifically, binding at site 1 results in allosteric activation of AMPK and 
binding at site 3 promotes phosphorylation. The alpha subunit is phosphorylated on 
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Thr172 in the activation loop increasing kinase activity of the Ser/Thr kinase domain at 
the amino terminus50. 
The best described AMPK-kinase is liver kinase B1 (LKB1). LKB1 is a known 
tumor suppressor and is mutated in the inheritable Peutz-Jeghers syndrome 
characterized by benign intestinal polyps and mucocutaneous pigmentation with an 
increased risk for developing tumors of multiple lineages. LKB1 functions in a complex 
with ste20-related adaptor (STRAD) and mouse protein 25 (MO25). Activation of AMPK 
by metabolic stress has been shown to be diminished in LKB1-null cells51. AMPK can 
also be activated by calcium-calmodulin kinase kinase 2 (CaMKK2), linking changes in 
intracellular [Ca2+] to activation of AMPK. Many other kinases have been reported to 
phosphorylate AMPK including transforming growth factor β-activated kinase (TAK1) and 
sestrins47. 
Once activated, AMPK signals downstream to restore cellular energy charge. 
AMPK promotes glycolysis through increased glucose transporter (GLUT) 1 and 4 
expression increasing glucose uptake as well as activation of 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase (PFKFB). AMPK also reduces protein synthesis 
through phosphorylation of tuberous sclerosis complex 2 (TSC2) and raptor resulting in 
inhibition of the mTOR pathway. Activation of AMPK promotes autophagy through direct 
phosphorylation of unc-51 like autophagy activating kinase 1 (ULK1) as well as through 
inhibition of mTOR. Moreover, AMPK inhibits fatty acid synthesis by inhibiting ACC, the 
enzyme responsible for converting acetyl-coA to malonyl-CoA the initial and rate limiting 
step of fatty acid synthesis. In addition, AMPK promotes beta oxidation of fatty acids by 
promoting the transcription of lipogenic enzymes via sterol regulatory element-binding 
transcription factor 1 (SREBP1) 48,50. 
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The role of AMPK in cancer is quite complex as it has been reported to function 
contextually as both a tumor suppressor or tumor promoter 49. AMPK can function as a 
tumor promoter by helping cancer cells to survive and adapt to metabolic stress that is 
characteristic of tumor microenvironments and oncogene activation. AMPK activation 
can allow cells to switch between fuel sources including glucose, glutamine and fatty 
acids, in order to tolerate nutrient deprivation and may activate a cell cycle arrest to 
allow tumor cells to survive particularly lean conditions. AMPK also plays a pro-survival 
role through activation of autophagy49.The role of AMPK as a mediator of the tumor 
suppressor properties of LKB1 has also been the focus of much research. Whole body 
knock out of AMPKα1 resulted in an increase in c-myc lymphoma development52 and 
expression of a dominant negative AMPK promoted prostate cancer cell proliferation53. 
Moreover, patients on metformin, an AMPK activator used in diabetes treatment, have 
Figure I-1: AMP-Activated Protein Kinase (AMPK) Pathway: AMPK is a heterotrimeric 
protein that is activated by an increase in the AMP/ATP Ratio. Binding of AMP at the γ 
subunit promotes phosphorylation of the α catalytic subunit by upstream kinases including 
LKB1 and CamKK2. Once activated AMPK feeds downstream to turn off ATP consuming 
processes and activate ATP generating processes. 
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been reported to have a lower incidence of cancers than metformin-naive diabetics48. 
Some of the tumor suppressor effects of AMPK have been attributed to its role in 
suppression of macromolecular synthesis pathways and its suppression of the Warburg 
effect. While acute AMPK activation promotes glycolysis, long term activation shifts cells 
towards a more oxidative phenotype by promoting mitochondrial biogenesis and 
transcription of oxidative enzymes. Moreover, inhibition of the mTOR pathway decreases 
translation of Hif-1α, a transcription factor that drives the Warburg effect51,52. Additional 
tumor suppressor functions of AMPK include the activation of cell cycle arrest through 
the stabilization of p53, p21 and p2751. Due to the decreased cancer incidence in 
metformin treated patients, considerable research has been directed towards developing 
metformin and other AMPK activators as cancer therapeutics.  
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Hypothesis: 
 
Based on published studies mentioned above and our preliminary results with 
tamoxifen and OXPHOS, we formulated the central hypothesis that tamoxifen inhibits 
oxygen consumption through an ER-independent direct effect on the mitochondria that 
results in significant alterations in metabolism and cell signaling that can be exploited for 
therapeutic benefit. To test this hypothesis, we first investigated the mechanism by 
which tamoxifen inhibits oxygen consumption. This work demonstrated that tamoxifen 
inhibits oxygen consumption by acting directly on the mitochondria, upstream of complex 
II and independently of ER signaling. We then characterized the consequences of 
tamoxifen inhibition of OXPHOS on cell signaling and metabolism. We have shown that 
tamoxifen treatment results in a rapid and robust activation of the AMPK pathway in vitro 
and in vivo, and downstream effects are mediated in an isoform specific manner. 
Tamoxifen treatment also results in an increase in glycolysis and alterations in fatty acid 
metabolism. We then determined if the metabolic effects of tamoxifen can be used for 
therapeutic benefit. This work demonstrates that combination of tamoxifen and glycolytic 
inhibitors synergize to cause increased cytotoxicity and that tamoxifen inhibition of 
OXPHOS can be used to target OXPHOS addicted cancer populations. Overall, this 
work describes a novel mechanism of action for an extensively used drug and identifies 
new therapeutic opportunities.  
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CHAPTER 2: TAMOXIFEN INHIBITS MITOCHONDRIAL COMPLEX I AND 
ACTIVATES THE AMPK PATHWAY. 
 
 
Sections of this chapter contribute to the published manuscript: 
 
Natalie A. Daurio, Stephen W. Tuttle, Andrew J. Worth, Ethan Y. Song, Julianne M. 
Davis, Nathaniel W. Snyder, Ian A. Blair, and Constantinos Koumenis.  AMPK 
activation and metabolic reprogramming by tamoxifen through estrogen receptor-
independent mechanisms suggests new uses for this therapeutic modality in 
cancer treatment. Cancer Res OnlineFirst March 28, 2016.
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Introduction: 
 
The anti-tumor effects of tamoxifen in BC are attributed primarily to its 
antiproliferative activity via competitive inhibition of the ER in breast tissue 6. Several 
studies have previously described non-ER dependent effects of tamoxifen such as the 
inhibition of Protein Kinase C (PKC)9 and the sensitization of ER-negative tumors to 
chemotherapeutic agents10. Furthermore,  during the past two decades, over 25 clinical 
trials have been published reporting the effects of “high dose” tamoxifen (i.e. doses 
above those needed to inhibit ER activity) ranging from 80 to 720 mg/day 12 to treat non-
breast cancers including glioma16, melanoma17 and others19,20, as a single agent or in 
combination with chemotherapeutics. While these Phase I and II trials showed variable 
clinical benefit, they clearly demonstrated the safety of high dose tamoxifen in diverse 
patient populations. Pharmacodynamic analyses indicated that  tamoxifen could reach 
plasma concentrations  as high as 8 µM19 and additional preclinical studies indicated that 
tamoxifen accumulates in tumor tissue at 60-70 times the plasma concentration21.  
Therefore, further studies on “high dose” tamoxifen are clinically relevant and may result 
in expanded indications for this affordable and well-tolerated chemotherapeutic.  
The chemical properties of tamoxifen as a lipophilic weak base contribute to its 
high partition into lipid bilayers and tamoxifen has been previously described to have 
inhibitory effects on mitochondrial  respiratory rate22 and membrane potential23. Cells in 
which oxidative phosphorylation (OXPHOS) is inhibited by pharmacologically targeting 
members of the mitochondrial respiratory chain, or due to lack of oxygen (hypoxia), 
exhibit a compensatory increase in glycolysis. For example, metformin, a diabetes drug 
showing promise as a cancer therapeutic, was recently demonstrated to inhibit 
Mitochondrial complex I and to upregulate glycolysis 42.  
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 One of the consequences of OXPHOS inhibition, especially in metabolically 
active cancer cells, is the activation of the AMP-activated protein kinase (AMPK), the 
major regulator of cellular energy homeostasis. AMPK is activated when the AMP:ATP 
ratio increases, signaling a loss in cellular energy charge. AMP binds to the gamma 
subunit of AMPK inducing a conformational change that prevents the dephosphorylation 
of the catalytic alpha subunit of AMPK by phosphatases. This enhances phosphorylation 
of AMPK by upstream kinases including LKB1 and CaMKK2. Once activated, AMPK 
restores cellular energy levels by promoting catabolic and inhibiting anabolic 
processes47.  The role of AMPK in cancer is quite complex as it has been reported to 
function contextually as both a tumor suppressor or promoter49. 
 Based on these studies, we investigated whether tamoxifen had an impact on 
cellular metabolism and metabolic signaling. Here we report the ability of tamoxifen to 
inhibit oxygen consumption, through a direct effect on mitochondria, upstream of 
complex II. We also observe rapid (<10 min) and acute activation of AMPK in vitro and in 
vivo in an ER-independent manner. Moreover, we demonstrate that activation of the 
AMPK pathway by tamoxifen promotes cell death in triple-negative breast cancer cells in 
an AMPK-isoform specific manner. 
 
Results: 
 
While tamoxifen has been reported to affect mitochondrial electron transport and 
membrane potential, its effects on oxygen consumption have not been adequately 
described. A Clark electrode was used to measure oxygen consumption of cells. 
Tamoxifen, at low M doses, inhibited oxygen consumption in a dose dependent manner 
in both ER+ MCF7 cells and triple-negative MDA-MB-231 cells (Figure II-1A).  Tamoxifen 
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also inhibited oxygen consumption in a panel of 6 non-breast cancer cell lines including 
prostate, glioma, lung and cervical cancer cell lines (Figure II-1B). The active metabolite 
of tamoxifen, 4-hydroxy-tamoxifen (4OH-Tam) also inhibited oxygen consumption while 
the ER antagonist fulvestrant, which inhibits ER activity by blocking ER dimerization and 
promoting degradation of the ER 54, did not have a significant effect  on oxygen 
consumption. Interestingly, supra-physiologic doses of estradiol, the endogenous ligand 
of the ER, also inhibited BC cell oxygen consumption (Figure II-1C). This suggests that 
inhibition of ER signaling is not responsible for the rapid inhibition of oxygen 
consumption in response to tamoxifen treatment. To further rule out involvement of ER 
signaling in tamoxifen-mediated inhibition of oxygen consumption, we used  both 
pharmacological and genetic means to knock down ER expression. Treatment of MCF7 
cells with fulvestrant reduced ER expression (Figure II-1D insert). Subsequent treatment 
with tamoxifen recapitulated the dose dependent effects on oxygen consumption seen 
with the control treated MCF7 cells (Figure II-1D). We then used the CRISPR-Cas9 
system to knock out ERα from LCC1 cells, a variant of the MCF7 line which expresses 
functional ER but is not dependent on its signaling for proliferation (Figure II-1E)55. The 
ability of tamoxifen to inhibit oxygen consumption in the LCC1-crspER cells was no 
different from the parental LCC1 cells (Figure II-1F) further supporting the notion that 
tamoxifen inhibits oxygen consumption independently of ER signaling. 
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Figure II-1: Tamoxifen Inhibits cellular oxygen consumption in an ER independent 
manner. A. Cellular oxygen consumption measurements in response to increasing doses of 
tamoxifen in ER+ MCF7 cells and ER- MDA-MB-231 cells. B. Fraction of oxygen 
consumption rate remaining after tamoxifen treatment at 30μM in a panel of cancer cell lines. 
C. Oxygen consumption measurements of BC cells treated with increasing doses of 
tamoxifen, 4OH-tamoxifen, fulvestrant, or β-estradiol. D. Oxygen consumption measurements 
of MCF7 cells pretreated with fulvestrant or vehicle control plus increasing doses of 
tamoxifen. Insert: Immunoblot of ER expression following fulvestrant treatment. E. Cellular 
oxygen consumption measurements of LCC1 cells and LCC1 cells with CRISPR-Cas9 
mediated deletion of ERα treated with increasing doses of tamoxifen. Data are the average of 
three independent experiments ±SEM, *P<0.05 **P<0.01 ***P<0.001.   
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To determine if the effect of tamoxifen on oxygen consumption was due to a 
direct interaction with mitochondria, we isolated mitochondrial from mouse liver. 
Tamoxifen inhibited oxygen consumption in the presence of complex I substrates 
glutamate and malate but not in the presence of complex II substrate succinate (Figure 
II-2A). To investigate if tamoxifen affected cancer mitochondria similarly to mitochondria 
isolated from healthy cells, we used digitonin to permeabilize MCF7 and MDA-MB-231 
cells.  Tamoxifen inhibited oxygen consumption of mitochondria by 60% in both 
permeabilized cell lines. As seen in liver mitochondria, respiration of cancer 
mitochondria could be rescued by supplementation with electron transport chain 
complex II substrate succinate but not with complex I substrates, glutamate and malate 
(Figures II-2B and II-2C). These effects of tamoxifen on mitochondria respiration are 
similar to what is seen with rotenone, a known complex I inhibitor. For experimental 
control we also determined that antimycin A, a complex III inhibitor, shuts down oxygen 
consumption in both permeabilized cell lines in the presence of succinate (Figures II-2B 
and II-2C). This indicates that the tamoxifen-mediated inhibition of oxygen consumption 
occurs through a direct effect on mitochondria, upstream of complex II.  Interestingly, 
while intact MCF7 cells exhibit higher oxygen consumption rate than MDA-MB-231cells, 
this difference is lost once the cells are permeabilized.  This may indicate that the higher 
rate of OXPHOS in MCF7 cells is due to a mechanism upstream of mitochondrial 
function. In addition, differing cell sensitivity to digitonin may play a role in the basal and 
succinate powered oxygen consumption rate. The addition of methyl succinate, a cell-
permeable analog of succinate, reduced the ability of tamoxifen to inhibit oxygen 
consumption in intact BC cells (Figure II-2D) and significantly increased cell survival of 
MCF7 cells treated with tamoxifen (Figure II-2E). These results suggest that inhibition of 
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mitochondrial function upstream of complex II mediates the effects of tamoxifen on 
oxygen consumption and downstream effects.  
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Upon inhibition of oxygen consumption, it is expected that ATP synthesis via 
OXPHOS would be reduced resulting in accumulation of AMP. To determine if inhibition 
of oxygen consumption by tamoxifen alters cellular energy charge we quantified 
intracellular AMP and ATP pools following tamoxifen treatment. Tamoxifen increased the 
AMP:ATP ratio in MDA-MB-231 cells and MCF7 cells (Figure II-3A), the major activating 
mechanism of AMPK, as soon as 5 min after tamoxifen treatment and this ratio further 
increased following one hour of treatment. This increase in the AMP:ATP ratio correlated 
with a concomitant increase in tamoxifen- induced AMPK phosphorylation of the 
downstream signaling target acetyl-CoA carboxylase (ACC) and dephosphorylation of 
the mTOR targets 70 kDa ribosomal protein s6 kinase 1 (p70S6K), ribosomal protein s6 
(pS6), and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), in both 
MCF7 (Figure II-3B) and MDA-MB-231 cells (Figure II-3C). To investigate if ER signaling 
is necessary for tamoxifen activation of the AMPK pathway, we used pharmacologic and 
genetic methods to block ER signaling. Pretreatment with fulvestrant to promote 
downregulation of the ER did not inhibit tamoxifen activation of AMPK (Figure II-3D).  
Furthermore, activation of AMPK in LCC1-crspER was comparable to that in LCC1 
parental cells (Figure II-3E), indicating that the effects of tamoxifen on AMPK signaling 
were also ER-independent. 
Previous Page - Figure II-2: Tamoxifen inhibits oxygen consumption at mitochondrial 
complex I: A. Oxygen consumption measurements of mitochondria isolated from mouse 
liver treated with tamoxifen in the presences of complex I or complex II substrates. B. Effect 
of tamoxifen on oxygen consumption of digitonin permeabilized MCF7 and C. MDA-MB-231 
cells in the presence of complex I or complex II substrates compared to other mitochondrial 
electron transport inhibitors rotenone and antimycin A.  D. Oxygen consumption 
measurements of MCF7 and MDA-MB-231 cells treated with Tamoxifen alone or in the 
presence of methyl succinate. E. Survival of MCF7 cells (N=6) treated with tamoxifen alone 
or in the presence of methyl succinate. Data are the average of three independent 
experiments ±SEM *P<0.05 **P<0.01. ***P<0.001.  
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Figure II-3: Tamoxifen rapidly and acutely activates AMPK independently of estrogen 
receptor signaling. A. HPLC quantification of the AMP:ATP ratio in MDA-MB-231 (N=6) and 
MCF7 (N=3) cells treated with 30 μM tamoxifen for 5 and 60 mins, ±SEM *P<0.05 **P<0.01. 
B. Immunoblot of AMPK pathway activation following treatment with 30μM tamoxifen in 
MCF7 and C. in MDA-MB-231 cells. D. Immunoblot analysis of ER expression and AMPK 
activation in MCF7 cells treated with 10 μM fulvestrant or DMSO for 4 hrs preceding 
treatment with 30 μM tamoxifen over time. E. Immunoblot of AMPK activation in LCC1 cells 
and LCC1 cells with CRISPR-Cas9 deletion of ERα following tamoxifen treatment.  
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Upon an increase in the AMP:ATP ratio in the cell, AMP binds the gamma 
subunit of AMPK which results in a conformational change that stabilizes 
phosphorylation of the alpha subunit. Multiple AMPKα kinases have been reported, we 
focused on the two most well-known: LKB1 and CaMKK2 to investigate their role in 
AMPK activation upon tamoxifen treatment in BC cells. We used siRNA to knock down 
expression of LKB1 and CaMKK2 in both MCF7 and MDA-MB-231 cell lines. In MCF7 
cells knock down of either LKB1 or CaMKK2 alone was not sufficient to prevent 
activation of AMPK. Concurrent knock down of both kinases was required to prevent 
AMPK phosphorylation (Figure II-4A). In MDA-MB-231 cells siRNA knock down of LKB1 
alone did not prevent tamoxifen-mediated phosphorylation of AMPK, while knock down 
of CaMKK2 was sufficient to inhibit phosphorylation of AMPK upon treatment with 
tamoxifen (Figure II-4A). However, under CaMKK2 knock down, treatment with 
tamoxifen still resulted in phosphorylation of the AMPK target ACC, indicating that AMPK 
was still activated even without phosphorylation as detected by immunoblot. This is 
consistent with reports noting that AMP binding is enough to activate AMPK kinase56. 
Similar to MCF7 cells, In MDA-MB-231 cells, knockdown of both LKB1 and CaMKK2 
prevented both AMPK phosphorylation and downstream signaling, as monitored by 
phosphorylation of the AMPK target ACC (Figure II-4A).  
During the course of these experiments, no antibody was available that 
accurately detected CaMKK2 expression by immunoblot, therefore we could not confirm 
successful knock down by siRNA. To confirm the effects of CaMKK2 knock down of 
AMPK activation following tamoxifen treatment we used the CaMKK2 inhibitor STO609. 
As expected, treatment with this drug had no effect on tamoxifen-mediated AMPK 
phosphorylation in MCF7 cells but did prevent phosphorylation of AMPK following 
tamoxifen treatment in MDA-MB-231 cells (Figure II-4B). Thapsigargin was used as a 
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control for CaMKK2-mediated AMPK phosphorylation. As expected, treatment with 
STO609 prevented AMPK phosphorylation following Thapsigargin treatment (Figure II-
4B). Overall, these results indicate that tamoxifen-mediated AMPK phosphorylation is 
mediated by multiple upstream AMPK-kinases and the extent of their importance is cell 
type specific.  
 
 
 
 
Figure II-4: LKB1 and CaMKK2 can both phosphorylate  AMPK in response to 
tamoxifen. A. Immunoblot of AMPK pathway activation with tamoxifen after siRNA knock 
down of LKB1 and CaMKK2 in MCF7 and MDA-MB-231 cells. B. Immunoblot of the effect of 
CaMKK2 inhibitor STO609 on Tamoxifen activation of AMPK.   
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To further dissect the biological role of AMPK in the cellular response to 
tamoxifen, we used the CRISPR-cas9 system to knock out AMPKα1 in MDA-MB-231 
cells. We observed that loss of AMPKα1 resulted in a compensatory increase in 
AMPKα2 expression (Figure II-5A) and induced an increased survival in response to 
tamoxifen treatment (Figure II-5B). This effect was recapitulated in MCF7 cells where 
AMPKα1 inhibition by shRNA resulted in reduced levels of cleaved PARP and increased 
survival upon tamoxifen treatment compared to shNT-transfected cells (Figures II-5C 
and II-5D). To evaluate the impact of complete inhibition of AMPK catalytic activity on 
cellular response to tamoxifen, we used siRNA to knock down AMPKα2 in both wild type 
MDA-MB-231 cells and in crspAMPKα1 cells. Loss of AMPKα2 in MDA-MB-231 cells 
resulted in increased cell death upon tamoxifen treatment whereas knockdown of 
AMPKα2 in the AMPKα1 CRISPR knockout cells resulted in further increase in 
tamoxifen-induced cytotoxicity (Figure II-5B). Notably, while the dual AMPKα1/2 
knockdown showed the highest levels of tamoxifen toxicity as determined by the 
modified MTT assay, the levels of apoptosis markers cleaved poly-ADP ribose 
polymerase (PARP) and cleaved caspase 3 were quite low. This could be due to more 
rapid processing of these markers under these conditions as indicated by complete loss 
of total PARP in these cells. Interestingly, knockdown of either isoform of AMPKα 
resulted in loss of phospho-ACC upon tamoxifen treatment, while loss of AMPKα1 alone 
ameliorated the inhibition of the mTOR pathway following tamoxifen treatment. Induction 
of autophagy remained unchanged upon AMPKα1 inhibition; however, knockdown of 
both isoforms substantially reduced autophagy levels as seen by a reduction in 
microtubule-associated protein light chain 3 (LC3) processing (Figure II-5A) 
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Figure II-5: AMPKα1 and AMPKα2 mediate divergent effects on downstream effectors 
and cellular survival after tamoxifen treatment.  A. Immunoblot of AMPK pathway 
activation and apoptotic markers after tamoxifen treatment in MDA-MB-231 cells with 
CRSPR-cas9 knock out of AMPKα1 or siRNA knock down of AMPKα2. B. Modified MTT 
assay of survival of AMPK knock down cells treated with 30 μM tamoxifen for 4 hrs. C. 
Clonogenic survival of the effect of AMPK knockdown by shRNA in MCF7 cells treated with 
30 μM tamoxifen. D. Immunoblot of AMPK activation and apoptotic markers following 
tamoxifen treatment of MCF7 cells transfected with shNT or shAMPKα1.  Data are the 
average of three independent experiments ±SEM *P<0.05 **P<0.01 ***P<0.001 
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To further investigate the role of AMPK isoforms in the autophagic response of 
BC cells to tamoxifen treatment we pretreated cells with E64d and pepstatin A to prevent 
LC3-II recycling and monitored autophagic flux by immunoblot. While we saw reduced 
levels of LC3-II in both siAMPKα2 and crspAMPKα1 conditions, MDA-MB-231 cells 
require both AMPKα1 and AMPKα2 to be knocked down in order to significantly reduce 
autophagy induction with tamoxifen treatment (Figure II-6A).  This data suggests that 
AMPK activation promotes autophagy in response to tamoxifen treatment.   
To determine if the AMPK isoform-specific effects on the mTOR pathway 
impacted upon cellular translation, we pulse-labeled MDA-MB-231 cells and 
crspAMPKα1 cells with [35S]-cysteine and methionine.  Translation was inhibited in both 
cell lines, albeit to a substantially lesser extent in the crspAMPKα1 cells upon tamoxifen 
treatment (Figure II-6B and II-6C).  
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To determine if tamoxifen activates the AMPK pathway in vivo, we injected 4175 
cells, a variant of the MDA-MB-231 triple negative breast cancer cell line57 into the 
mammary fat pad of athymic nude female mice. After 3 weeks of tumor growth, 100 
mg/kg tamoxifen was administered once daily for 3 days. Mean tamoxifen and 
metabolite levels of 4-hydroxy-tamoxifen and N-desmethyl-tamoxifen quantified by LC-
MS/MS in the tumor tissue were 19.07, 3.97 and 33.64 ng/mg respectively (Figure II-7A). 
This data indicates that the concentrations of tamoxifen needed to activate the AMPK 
pathway in vitro are achievable in vivo. Tumors in mice treated with tamoxifen also had 
significantly higher levels of phospho-AMPK and displayed downregulation of the mTOR 
target phospho-4-EBP1 (figure II-7B and II-7C). These results are in agreement with the 
tamoxifen-induced AMPK pathway activation seen in vitro. 
Previous page- Figure II-6: AMPKα isoform specific effects on downstream pathway 
mediators. A. Immunoblot of LC3-I and LC3-II flux with tamoxifen treatment as affected by 
AMPK status. Values represent Pixel intensity of LC3-I (top) or LC3-II (bottom) normalized to 
untreated control. B. Autoradiograph of 
35
S incorporation into proteins following tamoxifen 
treatment in MDA-MB-231 cells or MDA-MB-231 cells with CRISPR-cas9 knock out of 
AMPKα1. C. Quantification of 
35
S signal. Data are the average of three independent 
experiments ±SEM *P<0.05 **P<0.01 ***P<0.001. 
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Discussion: 
 
 We have demonstrated that beyond its anti-estrogenic effects, tamoxifen exerts a 
pronounced and immediate effect on tumor metabolism via a non-ER, mitochondrial-
specific pathway.  Specifically, through the inhibition of oxygen consumption upstream of 
complex II, the increase in AMP/ATP ratio leads to activation of AMPK. We also 
discovered a previously unreported dichotomy in the role of AMPK isoforms in tumor 
survival following metabolic stress. Whereas AMPKα1 primarily appears to promote cell 
Figure II-7: Activation of the AMPK pathway by tamoxifen in vivo. A. Tamoxifen and 
its metabolite levels in tumor tissue from 6 representative lysates following treatment of 
nude mice bearing 4175 tumors with tamoxifen (100mg/kg) for 3 days analyzed by LC-
MS/MS.  B. Representative Immunoblot of AMPK pathway activation in tumor lysates. C. 
Densitometry  analysis of signal intensity of Phos-AMPK normalized to total AMPK and 
Phos-4EBP1 normalized to β-Tubulin.  Data is the average ±SEM of N=17 per group, 
*P<0.05 **P<0.01. 
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death through inhibition of the mTOR pathway and translation, AMPKα2 promotes 
survival by a yet unidentified mechanism.  
While the clinical benefit of tamoxifen in ER+ breast cancer patients has been 
mainly attributed to inhibition of ER activity, tamoxifen has previously been shown to 
have multiple effects independent of ER. We have further characterized the effects of 
tamoxifen on mitochondria by describing the dose dependent effects on oxygen 
consumption to occur independent of ER. We have also demonstrated that AMPK 
activation occurs in both ER+ and ER- BC cells and that it is independent of ER signaling. 
In addition, tamoxifen activated the AMPK pathway in an orthotopic model of triple 
negative breast cancer. While we treated these animals for a short time at a high dose, 
we would anticipate similar effects at a lower dose over a longer period of time, as 
tamoxifen has been shown to accumulate in tumor tissues to levels up to 60-70 times 
the plasma concentration 21.  
 The non-ER dependent effects of tamoxifen described here, have the potential to 
expand the therapeutic window for tamoxifen into ER- BC and non-breast cancers.  
Furthermore, most ER+ BC related deaths have been attributed to metastatic disease 
which is often tamoxifen-resistant 6. While the mechanism by which tamoxifen resistance 
occurs remains unclear, it is thought to involve alterations in ER itself and alterations in 
the levels of co-regulators or downstream effectors in the signaling pathway 6.  Our 
results suggest that it would be valuable to further explore whether combination 
therapies that take advantage of the metabolic effects of tamoxifen could restore 
tamoxifen sensitivity or prevent resistance.   
The precise target for tamoxifen in the mitochondrial respiration chain is not 
currently clear. The evidence presented in this manuscript supports the hypothesis that 
tamoxifen inhibits complex I in the electron transport chain. The ability of the complex II 
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substrate succinate to restore oxygen consumption in tamoxifen treated cells points to 
the inhibition of mitochondrial respiration upstream of complex II. Moreover, the inability 
of complex I substrates glutamate and malate to restore any oxygen consumption in 
permeabilized BC cells indicates that complex I may be the site of tamoxifen action. 
However, we cannot completely rule out possible effects of tamoxifen on upstream 
processes, such as the TCA cycle, that contribute electron donors to the respiratory 
chain. Another implication of our findings with translational potential is the fact that 
inhibition of oxygen consumption is a validated strategy to increase tumor pO2 and 
decrease hypoxia, a major cause of cancer resistance to genotoxic therapy, including 
radiation46. Therefore, tamoxifen has the potential to function as a radiation and 
chemotherapeutic sensitizer. In fact, other complex I inhibitors, such as metformin, have 
shown anti-cancer effects through both their metabolic effects and activation of 
AMPK42,58. Although our results are reminiscent of the metabolic effects of metformin 
treatment, both the inhibition of oxygen consumption and activation of AMPK occur at a 
far more rapid rate (5-10 mins) than that seen with metformin (12-24 hrs). It is also 
important to note that while in vitro metformin exerts its OXPHOS-inhibitory effects at 
doses ranging from 1-50 mM, tamoxifen does so at low M concentrations.   
 The anti-tumorigenic effects of metformin in BC have been shown to be 
dependent on its activation of AMPK 58.  We asked if AMPK had a similar role in BC 
survival of tamoxifen treatment.  We used the CRISPR-cas9 system to delete AMPKα1 
from MDA-MB-231 cells and observed a compensatory increase in AMPKα2 expression. 
This would lead us to hypothesize that the isoforms have redundant effects, yet, we 
observed opposing effects on cell survival. Other work examining the isoforms of 
AMPKα has identified some differences,  AMPKα2-/- mice exhibit mild insulin resistance 
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and impaired glucose tolerance while AMPKα1-/- mice do not have a detectable 
metabolic phenotype59,60 . At the molecular level, AMPKα2 has been shown to be more 
reactive to AMP and is able to localize to the nucleus61. Moreover, AMPKα2 expression 
has been shown to be suppressed in primary BC62.  In our system, knock out of 
AMPKα1 alone rescued cells from tamoxifen treatment while knock down of AMPKα2 
increased cell death. Immunoblot analysis and [35S] labeling of proteins indicated that 
the α1 subunit is responsible for downregulation of the MTOR pathway and translation. 
However, both isoforms are needed to inhibit ACC and either isoform can activate 
autophagy. We suspect that it is the loss of robust autophagy induction in the dual 
AMPKα1α2 knockdown that results in increased tamoxifen cytotoxicity under those 
conditions. The ability of tamoxifen to activate autophagy is well established63,64 
however, the data reported here is the first to directly identify AMPK activation as a 
mechanism of autophagy induction in tamoxifen treated BC cells.  
In summary, we have described the ability of tamoxifen to inhibit oxygen 
consumption via an ER-independent direct effect of mitochondria, upstream of complex 
II. We have also shown that tamoxifen treatment results in robust AMPK activation and 
identified AMPK as a mediator of tamoxifen toxicity through isoform specific effects.
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CHAPTER 3: Characterization of the effects of tamoxifen on glucose and fatty acid 
metabolism and exploitation of the metabolic effects of tamoxifen for therapeutic 
opportunities.   
 
 
Sections of this chapter contribute to the published manuscript: 
 
Natalie A. Daurio, Stephen W. Tuttle, Andrew J. Worth, Ethan Y. Song, Julianne M. 
Davis, Nathaniel W. Snyder, Ian A. Blair, and Constantinos Koumenis.  AMPK 
activation and metabolic reprogramming by tamoxifen through estrogen receptor-
independent mechanisms suggests new uses for this therapeutic modality in 
cancer treatment. Cancer Res OnlineFirst March 28, 2016.
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Introduction: 
 
Tamoxifen treatment has been reported to affect multiple metabolic processes. 
These have included inhibition of mitochondrial function22,65,66, increased FDG-PET 
signaling following treatment67–69, and altered lipid homeostasis including decreased 
cholesterol levels4 and increased incidence of non-alcoholic fatty liver disease70. We 
have shown that tamoxifen mediated inhibition of oxidative phosphorylation results in 
metabolic stress characterized by an increase in AMP/ATP ratio and activation of the 
AMPK pathway. Activation of AMPK functions to rebalance cellular energy charge by 
turning off ATP consuming processes, including protein and fatty acid synthesis, and 
turning on ATP generating processes such as glycolysis, autophagy and fatty acid 
oxidation. As a result AMPK activation results in a significant reprogramming of cellular 
metabolic processes. AMPK activation promotes glycolytic activity by increasing glucose 
uptake through transporters GLUT171 and GLUT4  and activates glycolytic enzymes by 
increased transcription of hexokinase II and direct phosphorylation of 
phosphofructiokinase48,50. AMPK also shifts fatty acid metabolism from synthesis to 
oxidation. This occurs through the phosphorylation and inhibition on acetyl CoA 
carboxylase (ACC) the first committed step of fatty acid synthesis  and through 
decreased activity of SREBP1a, the transcription factor that controls gene expression of 
many lipogenic enzymes including FASN,  sterol-CoA desaturase 1 (SCD1) and 
glycerol-3-phosphate acetyltransferase (GPAT)48,50.  
In terms of metabolic targeted therapies, it has been postulated that concurrently 
targeting adaptive responses to metabolic reprogramming can lead to significant 
enhancement of the therapeutic window for multiple chemotherapeutic modalities72,73. 
Therefore the combination of tamoxifen with other metabolically targeted agents may 
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have therapeutic value. Moreover, oncogene activation results in increased dependence 
on upregulated metabolic pathways. For example, both BRAF and KRAS mutations 
promote glycolysis44,74. Resistance to targeted therapies limits the therapeutic options in 
cancers such as melanoma and pancreatic cancer that are driven by these pathways. 
The drug resistant populations are thus dependent on elevated OXPHOS and drugs that 
target mitochondrial metabolism, including metformin, have potential utility in targeting 
such resistant populations by synthetic-lethality approaches38,40,43,44. 
Here, we characterize the changes in cellular metabolism that occur with 
tamoxifen treatment. We show that tamoxifen treatment up regulates glucose uptake 
and glycolysis and concurrent treatment with tamoxifen and glycolytic inhibitors result in 
increased cell death. We also characterize the effects of tamoxifen on fatty acid 
metabolism. In addition, we demonstrate that tamoxifen treatment is toxic to OXPHOS 
addicted cancer cell populations.  
 
Results: 
 
AMPK activation is known to increase glycolytic activity in an attempt to restore 
cellular ATP pools47. To investigate if this occurred following tamoxifen treatment, we 
measured glucose uptake from the media in MDA-MB-231 and MCF7 cells. Glucose 
uptake increased in a dose-dependent manner with tamoxifen treatment in both cell lines 
(Figure III-1A). To examine if glycolysis was also upregulated by tamoxifen we analyzed 
the incorporation of [13C] from [13C6]-Glucose into acetyl-CoA and lactate by LC-MS/MS.  
Following tamoxifen treatment we observed an increase in [13C] labeling in these 
products, indicating an increase in glycolytic activity (Figure III-1B and III-1C). The 
activation of AMPK (P-AMPK) was enhanced under glucose deprivation conditions 
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(figure III-1D) and treatment with the glycolytic inhibitor 2-deoxyglucose (2DG) (figure III-
1E) in both MCF7 and MDA-MB-231 cells, underscoring the importance of the glycolytic 
switch for ATP generation during tamoxifen treatment. 
 
 
Figure III-1: Tamoxifen treatment promotes glycolysis. A. Glucose uptake from media 
following tamoxifen treatment for 1 hour in MCF7 and MDA-MB-231 cells. LC-MS/MS 
analysis of 
13
C6-glucose metabolites after 30μM tamoxifen treatment for 1 hour in MDA-MB-
231 cells: Mass isotopomer analysis of  B. Acetyl CoA and C. Lactate. N=4, **P<0.01 
***P<0.001.   D. Immunoblot analysis of phos-AMPK and total AMPK of cells treated with 
20µM tamoxifen over time under glucose deprivation or 5mM glucose. E. Immunoblot 
analysis of P-AMPK and total AMPK of cells treated with 20µM tamoxifen over time +/- 2DG. 
F. Immunoblot analysis of LC3-I and LC3-II in BC cells after tamoxifen treatment.  
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To investigate if glucose metabolism via the TCA cycle was altered with 
tamoxifen treatment we looked at [13C6]-Glucose labeling of TCA cycle intermediates 
citrate (Figure III-2A), malate (Figure III-2B), and succinyl-CoA (Figure III-2C). We 
observed a very small increase in the labeled fraction of citrate and succinyl-CoA but not 
of malate. While this data is statistically significant, the increase is very minor and is 
likely not physiologically significant and indicates that glucose metabolism through the 
TCA cycle is not changed with tamoxifen treatment. In addition to entering the TCA 
cycle, the acetyl-CoA that is created from glucose as an end product of glycolysis can 
also enter fatty acid metabolism pathways through conversion to malonyl-CoA by the 
enzyme ACC. ACC is an AMPK target and phosphorylation of ACC by AMPK inhibits 
enzyme function. ACC is the main AMPK target responsible for reduction of fatty acid 
synthesis upon loss of intracellular ATP.  We analyzed [13C]6-Glucose label 
incorporation into malonyl-CoA following tamoxifen treatment and observed an increase 
in labeled fraction in tamoxifen treated cells (Figure III-2D) indicating that a larger 
amount of malonyl-CoA is derived from glucose following tamoxifen treatment. These 
results were unexpected, given that AMPK activation should reduce malonyl-CoA 
synthesis. However, with a large increase in glycolytic activity upon tamoxifen treatment 
it is possible that the increase in malonyl-CoA labeled fraction from glucose is due to 
substrate excess.  
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Since we demonstrated that tamoxifen blocks OXPHOS and concurrently 
increases glucose uptake and utilization, it is likely that effective strategies for metabolic 
targeted therapies may require the inhibition of both OXPHOS and glycolysis 
simultaneously. 2DG, a non-metabolisable analog of glucose and 3-Bromopyruvate 
(3BP), an alkylating agent and inhibitor of hexokinase-2 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), induced a dose-dependent decrease in glucose 
uptake, as expected (Figure III-3A and III-3C). More importantly, combined treatment 
with relatively non-toxic doses of each of these inhibitors with tamoxifen significantly 
Figure III-2: 
13
C6-Glucose labeling of TCA cycle intermediates and malonyl-CoA. 
Isotopomer analysis by LC-MS/MS of [
13
C6]-glucose label incorporation into A.  Citrate B. 
malate C. succinyl-CoA and D. malonyl-CoA. Data are the average of four independent 
experiments ±SEM *P<0.05 **P<0.01 ***P<0.001.  
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enhanced tamoxifen-induced cytotoxicity in MCF7 cells and in MDA-MB-231 cells 
(Figures III-3B and III-3D). Notably, the sensitization to tamoxifen was larger in the MDA-
MB-231 cells, which display a higher basal rate of glucose uptake (Figure III-3A) and 
lower basal level of OXPHOS (Figure II-1A).  
We then tested if combination of tamoxifen with glycolytic inhibitors were 
effective in reducing tumor growth in an in vivo model of triple negative breast cancer. 
The MDA-MB-231 variant 4175 cells were injected orthotopically into the mammary fat 
pad. Mice were randomized into four groups: vehicle control, tamoxifen only, 3BP only 
and tamoxifen plus 3BP. Two weeks after tumor implantation, mice were given a loading 
dose of tamoxifen, followed by a maintenance dose of 25 mg/kg every 3 days. 3BP was 
given daily at 5mg/kg. Tumor growth was monitored twice weekly for 35 days. While the 
treatment was tolerable, no difference in tumor growth was seen between any treatment 
groups and control mice (Figure III-3E). Multiple factors may be responsible for the lack 
of efficacy seen in this model. Dose limiting toxicity of 3BP was significant; therefore, it 
may be that the tolerable dose was not high enough to reduce glycolysis in the tumor. 
Moreover, tumor growth in this model is quite slow, and may be that the metabolic stress 
induced by this treatment combination would be effective in a more aggressive model.  
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Figure III-3: Tamoxifen treatment synergizes with glycolysis inhibitors. A. Glucose 
uptake measurements in BC cells treated with 2DG. B. Survival of BC cells treated with 
2DG and tamoxifen or tamoxifen alone. C. Glucose uptake measurements in BC cells 
treated with 3-BP. D. Survival of BC cells treated with 3-BP and tamoxifen or tamoxifen 
alone. Data are the average of three independent experiments ±SEM *P<0.05 **P<0.01 
***P<0.001. E. Measurements of 4175 tumor volume ±SEM over time in in nude mice 
treated with vehicle control, 3BP only, Tamoxifen only, or both 3BP and Tamoxifen. N=20 
per group. 
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Synthesis of fatty acids (FAs) which begins with the synthesis of malonyl-CoA 
from acetyl-CoA, are of particular importance in cancer due to the need to generate 
excess membranes for rapid proliferation. Moreover, the oxidation of FAs in the 
mitochondria can replenish cellular ATP levels during times of metabolic stress75.  To 
examine if tamoxifen impacted FA metabolism, we performed metabolite analysis of fatty 
acyl-CoA species by LC-MS/MS. The analysis showed an accumulation of acetyl-CoA 
and malonyl-CoA following tamoxifen treatment (Figure III-4A). We also observed a 
reduction in succinyl-CoA and other medium chain acyl-CoA species (C3:0, C6:0) 
consistent with reports of the effects of other complex I inhibitors76 and an accumulation 
of longer chain (C16-C20) acyl-CoA species (Figure III-4A). The addition of [13C]-glucose 
or [13C]-glutamine resulted in no labeling of the long-chain CoA metabolites, indicating 
that these fatty acyl-CoAs are not synthesized from glucose or glutamine de novo in 
response to tamoxifen treatment. It has been reported that under metabolic stress, cells 
switch from glucose and glutamine to acetate as a carbon source for fatty acid 
synthesis77. Indeed, upon tamoxifen treatment, labeling from [14C]-acetate of the cellular 
lipid fraction increased (Figure III-4B). 
Activation of the AMPK pathway is also known to promote β-oxidation of fatty 
acids as a strategy to increase ATP pools. The degradation of lipid droplets by 
autophagy, termed lipophagy, increases the supply of free FAs which are then 
transported into the mitochondria for oxidation75. We also observed a rapid activation of 
autophagy upon tamoxifen treatment (Figure III-1F). BODIPY 493/503 stain, which 
measures total neutral lipid content in the cell, decreased in cells treated with tamoxifen 
(Figure III-4C). These data suggest that the accumulation of the long chain acyl-CoA 
species results from breakdown of lipid droplets.  
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To further probe the role of fatty acid metabolism in the cellular response to 
tamoxifen treatment we supplemented the cell culture media with oleic acid conjugated 
BSA. Supplementation with oleic acid completely rescued MDA-MB-231 cells from 
tamoxifen cytotoxicity (Figure III-4D). Moreover, oleic acid restored mTOR activity as 
determined by immunoblot (Figure III-4E). However, oleic acid supplementation was not 
sufficient to inhibit AMPK phosphorylation upon tamoxifen treatment.  
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 Acquired resistance to BRAF inhibitors in melanoma was recently shown to 
elevate oxygen consumption rate in the resistant cell population40. Therefore, we tested 
the effects of tamoxifen as a treatment in an in vitro model of OXPHOS addiction in 
cancer. We confirmed the previously reported increase in oxygen consumption rate in 
melanoma cells WM9 and 1205Lu selected over 3 days for a population that was 
resistant to the BRAF inhibitor PLX4720 (Figure III-5A and III-5B). We observed that 
tamoxifen inhibited oxygen consumption in this resistant population as well as the 
parental melanoma cell lines (Figure III-5A and III-5B). Tamoxifen induced cytotoxicity 
was then determined in the PLX4720 resistant population and the parental melanoma 
cell lines. The PLX4720-resistant population was more sensitive to tamoxifen (Figure III-
5C and III-5D). Collectively, this data strongly suggests that tamoxifen can be used in 
combination with other therapies to effect robust anti-tumor effects via metabolic stress. 
Previous page-Figure III-4: Tamoxifen alters fatty acid metabolism:  A. LC-MS/MS 
metabolomic analysis of acyl-CoA species in MDA-MB-231 cells with and without 
tamoxifen treatment. B. quantification of 
14
C-acetate radiolabel incorporation into total 
cellular lipid fraction. C. Flow cytometry quantification of BODPIY 493/503 stain intensity 
and representative images of BODIPY staining in control and tamoxifen treated MDA-MB-
231 cells. D. Effect of oleic acid supplementation on the survival of MDA-MB-231 cells 
treated with tamoxifen. E. Immunoblot of the effect of oleic acid supplementation on 
tamoxifen inhibition of the mTOR pathway in MDA-MB-231 cells.  Data is the average of 
three independent experiments +/- SEM. *P<0.05, **P<0.01, ***P0.001. 
 
Next Page - Figure III-5: Tamoxifen inhibits OXPHOS and is cytotoxic to BRAF-
Inhibitor resistant melanomas. BRAF mutant melanoma line WM9 and 1205Lu were 
treated with BRAF inhibitor PLX4720 for three days to select for a resistant population. A. 
Oxygen consumption measurements of  the PLX4720 resistant population and the 
parental melanoma cell lines  WM9 and B. 1205Lu treated with tamoxifen. C. Survival of  
the PLX4720 resistant population and the parental melanoma cell lines  WM9 and D. 
1205Lu treated with tamoxifen. Data is the average of three independent experiments +/- 
SEM. *P<0.05, **P<0.01, ***P0.001. 
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Discussion: 
 
We have demonstrated that tamoxifen treatment increases glycolysis and cellular 
dependence on glycolytic activity for cell survival. This can be exploited for therapeutic 
benefit via combination treatment with tamoxifen and glycolytic inhibitors. We have also 
shown that tamoxifen alters cellular fatty acid metabolism through inhibition of fatty acid 
synthesis and depletion of intracellular lipid stores. Supplementation with fatty acids can 
-R 
-R 
-R -R 
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rescue cells from tamoxifen treatment, highlighting the importance of fatty acid oxidation 
under tamoxifen treatment conditions. 
 Tamoxifen inhibition of oxygen consumption results in an increase in the cellular 
AMP:ATP ratio and the activation of the AMPK signaling pathway and an increase in 
glycolytic activity. Other activators of AMPK, such as metformin, have also been shown 
to increase dependence on glycolysis.  Intriguingly, soon after BC patients begin 
treatment with tamoxifen, a “metabolic flare” is often seen in their FDG-PET scans67,69. 
Although the cause for this radiologic abnormality has not been clearly delineated, it is 
reasonable to hypothesize that this could be due to increased uptake of FDG in 
response to metabolic reprogramming and AMPK activation, since GLUT 1 transporters, 
the major transporter system of glucose and FDG uptake, are AMPK targets71.  
We have also demonstrated the potential for increased therapeutic benefit 
through drug combinations with tamoxifen that have a synergistic effect via blockade of 
upregulated metabolic pathways. Glycolytic inhibitors have long been attractive clinical 
agents due to the Warburg effect, yet systemic toxicity has limited their success in the 
clinic. 2DG has been tested in clinical trials and 3BP has shown significant preclinical 
potential78 .Our data suggests that clinical use of these inhibitors in combination with 
tamoxifen may result in increased efficacy and use of reduced doses that may limit 
toxicity. 
While tamoxifen synergized with glycolytic inhibitors in vitro, combined treatment 
with tamoxifen and 3BP did not impact tumor growth in an in vivo model of triple 
negative breast cancer. The lack of efficacy in vivo may be due to multiple factors. First, 
3BP is quite toxic and it is possible that the tolerated dose was not high enough to 
significantly reduce glycose metabolism in tumors. Tamoxifen has also been reported to  
inhibit of angiogenesis79 which may further reduce drug delivery to the tumor. Tamoxifen, 
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a highly lipophilic drug, was delivered in peanut oil. Our in vitro data has shown that 
supplementation with fatty acids can rescue cells from tamoxifen cytotoxicity.  Therefore, 
using lipids as the drug vehicle may have countered the effects of tamoxifen treatment or 
available fatty acids from circulation or tumor microenvironment may have also 
contributed to the lack of efficacy.  Another possible explanation for the lack of in vivo 
efficacy may be the chosen tumor model. Rodent triple negative BC models progress 
quite slowly and it may be that the tumor can tolerate more metabolic stress due to low 
proliferation rate. It would be worthwhile to test the combination of tamoxifen and 
glycolytic inhibition in a more aggressive tumor model.    
Our results are also in agreement with other metabolic effects of tamoxifen in 
patient populations. Women on tamoxifen therapy have an increased risk for developing 
non-alcoholic fatty liver disease70. However, the effects of tamoxifen on tumor fatty acid 
metabolism have not been investigated in detail. Accumulation of malonyl-CoA following 
tamoxifen treatment has been previously reported80 and we also observed this in BC 
cells. The synthesis of malonyl-CoA is the rate-limiting step in fatty acid synthesis, thus 
its accumulation leads us to suspect that there is a decrease in the activity of FASN 
which is consistent with AMPK activation. It is also possible that increased upstream 
flux, through glycolysis and acetate utilization, contributes to the accumulation of 
malonyl-CoA with tamoxifen treatment. It is worth noting that AMPK is also known to 
inhibit fatty acid synthesis and promote β-oxidation, primarily through inhibiting ACC47. 
Metabolic labeling indicates that acetate and not glucose or glutamine functions as the 
carbon source for fatty acid synthesis during tamoxifen treatment. The propensity for 
cells to switch to acetate utilization under metabolic stresses including hypoxia and 
nutrient deprivation has been previously reported77 and it is not surprising that it occurs 
under tamoxifen-generated metabolic stress as well.  
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Depletion of intracellular lipid stores and accumulation of long chain fatty acyl-
CoAs are consistent with an increase in beta oxidation which is also expected under 
AMPK activation conditions. Due to the robust activation of autophagy we previously 
described under tamoxifen treatment we suspect that lipophagy plays a significant role in 
replenishing or maintaining ATP during metabolic stress via the release of free fatty 
acids from lipid droplets75. It is important to note that β-oxidation generates both NADH 
and FADH2. Under conditions of complex I inhibition, the FADH2 generated via oxidation 
of fatty acids could feed into electron transport via complex II, similar to what is seen 
with the addition of succinate, to power ATP synthesis.  The ability of oleic acid to rescue 
translation as well as survival highlights the dependence of tamoxifen treated BC cells 
on fatty acid metabolism for survival.  
Interestingly, malonyl-CoA is known to inhibit carnitine palmitoyltransferase 
(CPT-1), the transporter responsible for transporting free fatty acids into the 
mitochondria for β-oxidation. As a result, it would be expected that β -oxidation would be 
decreased under tamoxifen treatment conditions due to the large accumulation of 
malonyl-CoA. Therefore it is possible that the ability of oleic acid to rescue tamoxifen 
treatment is not due to providing a substrate for ATP generation via β-oxidation but 
through providing fatty acids for membrane generation as tamoxifen has been reported 
to accumulate in lipid bilayers and likely damage cellular membranes. More experiments 
would be required to investigate the effects tamoxifen has on cellular membranes and 
whether oleic acid supplementation contributes to membrane repair.  
Recognition of cancer as a heterogeneous disease has led to the development of 
personalized medicine and targeted therapies. Drugs designed to inhibit specific 
activated oncogenes often have early success, but are plagued by the emergence of 
resistance. If the pathways that contribute to resistance can be identified and inhibited, it 
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is reasonable to infer that resistance may be prevented or delayed. Resistance to BRAF 
and KRAS target therapies has been described to require increased dependence on 
OXPHOS. Our data shows that tamoxifen mediated inhibition of OXPHOS in this 
resistant population results in increased cell death. Therefore, the combination of 
tamoxifen with these targeted therapies may increase clinical response.    
In conclusion, we have characterized the impact of tamoxifen treatment on 
glucose and fatty acid metabolism. These metabolic changes highlight pathways that 
may be essential for cell survival of tamoxifen treatment. We have demonstrated that 
glycolytic activity is required in tamoxifen treated cells and combination of tamoxifen and 
glycolytic inhibitors may be an effective therapeutic strategy. Additional in vivo models 
would be necessary to further test this hypothesis. Moreover, OXPHOS addiction is 
characteristic of resistance to BRAF and KRAS targeted therapies and tamoxifen 
inhibition of respiration is preferentially cytotoxic to this population and may be of clinical 
use to overcome resistance.  
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CHAPTER 4: Conclusions and Future Directions
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Chapters II and III collectively describe a novel mechanism of action for tamoxifen, an 
extensively used drug for ER+ BC treatment (Figure IV-1). Tamoxifen inhibits oxygen 
consumption at complex I of the mitochondrial respiratory chain resulting in a decrease 
in oxygen consumption and increase in the intracellular AMP/ATP ratio.  AMPK 
activation impacts cell survival through isoform specific downstream signaling. 
Tamoxifen treatment also results in an increase in glycolysis as well as alterations in 
fatty acid metabolism including break down of neutral lipid droplets, accumulation of long 
chain fatty acyl-CoAs, and an increase in acetate utilization (Figure IV-1). These 
metabolic effects of tamoxifen suggest strategies by which clinical efficacy may be 
increased through synergy with pharmacological targeting of upregulated metabolic 
pathways.   
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Tamoxifen inhibition of Oxygen consumption 
Chapter II describes a novel mechanism by which tamoxifen treatment inhibits 
cellular oxygen consumption. Tamoxifen acts directly on the mitochondria, upstream of 
complex II, independently of ER signaling. We see inhibition of oxygen consumption 
across a panel of multiple cancer cell lines, therefore these effects have the potential to 
expand the use of tamoxifen beyond ER+ BC. Through degradation of ERα by 
fulvestrant and knock out using CRISPR-cas9 we have demonstrated that ERα signaling 
does not contribute to the effects of tamoxifen on respiration. However, the impact of 
ERβ signaling on tamoxifen inhibition of oxygen consumption was beyond the scope if 
this work. ERβ and ERα have both overlapping and distinct biological functions. ERβ is 
expressed in breast tissue but has been reported to be downregulated in BC due to 
promotor methylation, suggesting it may function as a tumor suppressor. However 
immunohistochemical staining shows ERβ expression in approximately 2/3 of BC 
samples81. Tamoxifen functions as an ERβ antagonist82  but the role of  ERβ  in 
response to therapy remains unclear. ERβ expression is correlated with improved 
survival83 but has also been shown to be increased in tamoxifen resistant cases84. 
Important for elucidating the metabolic effects of tamoxifen is the reported expression of 
ERβ in mitochondria85,86. While we did not test whether ERβ signaling contributes to the 
ability of tamoxifen to alter respiration, it is unlikely. Inhibition of oxygen consumption 
occurs within 2 minutes of the addition of tamoxifen, indicating that these effects are 
likely not the result of transcriptional changes promoted by nuclear receptors. However, 
Previous page – Figure IV-1: Model of the effects of Tamoxifen on metabolism.  Tamoxifen 
inhibits oxygen consumption at complex I of the mitochondrial electron transport chain. This 
increases the AMP/ATP ratio and activates AMPK. Downstream effects of AMPK activation 
on cell survival, translation and autophagy are mediated in an isoform specific manner. 
Tamoxifen treatment also increases cellular dependence on glycolysis and alters fatty acid 
metabolism. 
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more experiments would be needed to determine if ERβ contributes to the effects of 
tamoxifen on BC cell metabolism. 
This study suggests that tamoxifen is an inhibitor of electron transport chain 
complex I. Complex I inhibitors have become of particular interest as cancer 
therapeutics due to the anti-cancer properties of metformin, a reported complex I 
inhibitor42.  However, many complex I inhibitors such as rotenone are highly toxic. Our 
data demonstrates that tamoxifen inhibits oxygen consumption faster and at lower doses 
than metformin. The data reported in this study as well as numerous clinical trials 
demonstrating the safety of tamoxifen at a large range of dosages support the clinical 
use of tamoxifen as a safe and well tolerated complex I inhibitor. However, we cannot 
completely rule out other mitochondrial targets. Previous studies have reported 
tamoxifen to alter the mitochondrial membrane potential23,65 and inhibit at complex III87. 
While our data does not support these mechanisms, future studies such as binding 
assays and crystallography would be necessary to determine the exact interaction site of 
tamoxifen with mitochondria.   
 The many phase I/II clinical trials that explored high dose tamoxifen as a single 
agent or in combination with cytotoxic chemotherapeutics demonstrated safety, but little 
clinical efficacy. Our in vitro data suggests that tamoxifen treatment may be effective in 
combination with other metabolically targeted agents, such as glycolytic inhibitors. 
Moreover, this study also suggests that tamoxifen may be effective in combination with 
oncogene targeted therapy. Future work would be necessary to demonstrate the efficacy 
of these combinations in vivo. It would also be worthwhile to investigate the ability of 
tamoxifen to function as a radiosensitizer. Tumor hypoxia significantly limits the success 
of radiotherapy for cancer treatment. The presence of intracellular oxygen enhances the 
effect of radiation induced DNA damage through the “oxygen effect”. Ionizing radiation 
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results in the generation of carbon centered radicals in DNA and proteins which can be 
repaired by hydrogen donors in the cell, a process known as chemical restitution. In the 
presence of oxygen, peroxidation of radicals occurs in a process known as damage 
fixation.  These peroxy radicals cannot be repaired, resulting in increased DNA damage 
and cell death88. To date, strategies to reduce hypoxia for radiosensitization have not 
achieved regular clinical use. An agent that decreases tumor oxygen consumption has 
the potential to act as a radiosensitizer or enhancer because it would increase local pO2 
and reduce hypoxia46. Such compounds including metformin89, nelfinavir90, and 
PI3K/mTOR inhibitors91 have been shown to reduce hypoxia and radiosensitize tumors. 
Atovoquone, an anti-malarial drug that targets mitochondrial electron transport complex 
III92, is also in clinical trials as a radiosensitizer.  In addition to reducing oxygen 
consumption, metformin has also been shown to act as a radiosensitizer through AMPK 
dependent mechanisms93,94. Based on this literature and the data described in this 
study, it would be reasonable to hypothesize that tamoxifen would reduce tumor hypoxia 
and function as a radiosensitizer. Additional experiments in vitro and in vivo are needed 
to test this.  
   
Tamoxifen activation of AMPK 
 Chapter II describes tamoxifen as a novel activator of AMPK. Tamoxifen 
treatment results in an increase in the AMP/ATP ratio and phosphorylation of AMPKα.  
Activation of AMPK by tamoxifen further supports the hypothesis that tamoxifen acts as 
a complex I inhibitor as well as the use of tamoxifen as a metabolically targeted 
therapeutic. Multiple kinases have been reported to phosphorylate AMPK. In this study 
we explored the role of the two most prominent AMPK-Kinases, LKB1 and CaMKK2 in 
the mechanism by which tamoxifen activates AMPK. Using both genetic and 
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pharmacological means, we determined that both kinases play a role in AMPK activation 
following tamoxifen treatment and that their prominence is largely cell type dependent. 
CaMKK2 has been shown to phosphorylate AMPK in response to AICAR treatment in 
cells lacking LKB195. However, CaMKK2 also activates AMPK in response to an 
increase in intracellular calcium concentrations96. Therefore, the role of CaMKK2 in 
activation of AMPK following tamoxifen treatments poses the question of whether 
calcium dysregulation by tamoxifen may also be involved. Tamoxifen has been 
previously shown to alter calcium signaling in BC and glioma cells97. In order to 
determine if this effect is involved in activation of AMPK, chelators such as BAPTA-AM 
could be used.  AMPK is also allosterically activated by AMP binding, even without 
phosphorylation of the AMPKα56, our data agrees with these reports as we see 
phosphorylation of ACC with tamoxifen treatment even without phosphorylation of 
AMPK.  
 The role of AMP allosteric activation of AMPK as well as the involvement of 
CaMKK2 in tamoxifen-mediated activation of AMPK is important to note because LKB1 
is a tumor suppressor and is frequently lost in cancers. Recent studies have shown that 
phenformin is effective as a single agent in a mouse model of KRAS LKB1-/- NSCLC, 
suggesting that AMPK activators may be therapeutic in LKB1-/- cancers98. Thus our data 
suggests that tamoxifen treatment may also be effective in these cancers. 
 Chapter II describes the role of AMPK in BC cell survival of tamoxifen treatment 
to be mediated by isoform specific effects. We see protection from tamoxifen mediated 
cytotoxity in CrspAMPKα1 knock out cell, while loss of AMPKα2 results in increased cell 
death. In our system, both isoforms are needed to inhibit ACC, while inhibition of the 
mTOR pathway is AMPKα1 dependent, yet activation of autophagy can be promoted by 
either isoform. Upon loss of AMPKα1 we see increased AMPKα2 expression and it 
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remains unclear whether it is the loss of AMPKα1 or overexpression of AMPKα2 that 
rescues cells from tamoxifen. Moreover, it is still unclear which downstream targets are 
responsible for the survival effects of each isoform and more work would be needed to 
elucidate these specific mechanisms. While this work identifies potentially novel isoform 
specific roles for AMPKα in mediating downstream signaling effects, it is important to 
recognize that these differences may be both cell type dependent as well as stress 
dependent. More work would be needed to determine reproducibility across multiple 
contexts. 
 
Tamoxifen alters glucose and fatty acid metabolism 
 Chapter III aims to characterize the metabolic changes that accompany 
tamoxifen inhibition of OXPHOS. It is well established that inhibition of respiration results 
in an upregulation of glycolytic activity and this effect is seen in tamoxifen treated BC 
cells as well. Using [13C6]-glucose labeling we see the contribution of glucose carbons to 
lactate, acetyl-CoA, and malonyl-CoA to be increased with tamoxifen treatment. 
However we do not see a significant change in labeled-glucose incorporation into the 
TCA cycle. Inhibition of OXPHOS is often correlated with a reduction in TCA cycle 
activity due to the buildup of NADH and FADH2. This study did not examine total levels 
of TCA cycle intermediates, therefore it is possible that tamoxifen reduces overall TCA 
cycle activity, without any change in the percent labeling from glucose. It would be 
important to further examine the effects of tamoxifen on TCA cycle activity as many of 
the intermediates can be used for synthesis of other essential macromolecules such as 
amino acids and nucleotides99,100. Moreover, investigating whether there is any change 
in the NAD+/NADH and FAD/FADH2 levels upon tamoxifen treatment would also be 
worthwhile. Further examination of TCA cycle activity, amino acids and nucleotide 
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synthesis pathways, as well as reducing equivalents upon tamoxifen treatment could 
potentially identify opportunities to increase tamoxifen response by targeting these 
altered pathways. 
Chapter III also reports significant changes in fatty acid metabolism upon 
tamoxifen treatment. Acyl-CoA quantification showed an unexpected accumulation of 
long chain CoA species. Labeling experiments indicated that these were not synthesized 
de novo from glucose or glutamine and accumulation of malonyl-CoA suggests an 
inhibition of FASN. Loss of total neutral lipid content in the cell suggests the source of 
these free fatty acids to be break down of lipid droplets.  However, we did see an 
increase in acetate label incorporation into the total lipid pool upon tamoxifen treatment. 
Yet this experiment did not identify what species of lipids were labeled with 14C acetate, 
nor did it quantify the total levels of any species. As a result the interpretation of this data 
is quite limited. It suggests that BC cells treated with tamoxifen shift the fatty acid carbon 
source from glucose or glutamine to acetate, which is in agreement with previous reports 
of cells under metabolic stress77. Further investigation into cellular acetate metabolism 
with LC-MS/MS analysis of 13C acetate labeling into the acyl-CoAs would provide 
additional clarity. Moreover, if acetate utilization is required in tamoxifen treated cells, 
ACSS2, the enzyme that converts acetate to acetyl-CoA may be a good target to 
increase tamoxifen efficacy.  
Supplementation of BC cells with oleic acid completely rescues cells from 
tamoxifen treatment and restores mTOR activity. It is easy to hypothesize that these 
effects are due to β-oxidation generation of ATP and macromolecular intermediates. 
However, elevated malonyl-CoA levels seen with tamoxifen treatment suggest that the 
CPT-1 transporter is inhibited. Therefore β-oxidation would be blocked under these 
conditions.  LC-MS/MS analysis of 13C labeled oleate incorporation into short chain Acyl-
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CoA’s would provide insight into whether oleic acid undergoes β-oxidation. Another 
possible explanation for the pro-survival effects of oleic acid on tamoxifen treated cells 
could be the use of oleic acid to repair damaged membranes. Tamoxifen has been 
shown to accumulate in, and alter the properties of cellular membranes101,102.  More 
experiments would be needed to assess the extent to which intracellular membranes are 
compromised by tamoxifen treatment and if oleic acid plays any role in repair.  
  
Therapeutic opportunities exploiting the metabolic effects of tamoxifen  
 Metabolic flexibility allows for the upregulation of pathways to compensate for a 
physiological or pharmacological blockade. This plays a role in ability of cancer cells to 
survive nutrient deprivation characteristic of the tumor microenvironment as well as 
limited the use of metabolically targeted agents. It has been postulated that dual 
targeting of these compensatory pathways would improve the efficacy of metabolically 
targeted therapeutics 
Our data suggest that combination treatment with tamoxifen and glycolysis 
inhibitors may be clinically effective, however in an in vivo mouse model of triple 
negative BC, we did not see any effect on tumor growth with tamoxifen and the glycolytic 
inhibitor 3BP. The lack of efficacy in vivo may be due to multiple factors including the 
resistance of slowly proliferating tumors to metabolic stress, delivery of tamoxifen in a 
lipid vehicle, and dose limiting toxicity of 3BP. Additional studies are warranted to 
determine if this combination treatment could be effective in reducing tumor growth in 
other models. The development of improved glycolytic inhibitors is also greatly needed. 
No available glycolytic inhibitors have reached regular clinical use despite being 
extensively studied. Limitations to the development of such compounds include the 
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ubiquitous expression of glycolytic enzymes in all tissues and the dependence of 
sensitive organs such as the brain on glucose metabolism31,103. 
 Chapter III also describes the success of tamoxifen as a treatment in OXPHOS 
addicted tumor cell populations. Inhibition of oncogenes that promote the Warburg effect 
by targeted therapies result in increased respiration in resistant populations. These 
resistant populations result in therapeutic failure and disease progression in patients. 
Using a model of BRAF-inhibitor resistant melanoma, treatment with tamoxifen can 
reduce oxygen consumption preferentially kill the resistant cells.  We hypothesize that 
the increased cell death is due to the inability of these cells to respire in the presence of 
tamoxifen and the ensuing metabolic stress. However we have not determined the exact 
mechanism by which tamoxifen results in cytotoxicity in this population. More 
experiments would be necessary to determine if loss of ATP and activation of AMPK, 
loss of reducing equivalents and an increase in ROS, as well as inability of these cells to 
synthesize macromolecular intermediates contributes to cell death.  In addition, 
Investigating whether this effect occurs in vivo would be necessary to determine whether 
the addition of tamoxifen treatment to BRAF-inhibitors improves survival and reduces 
recurrence in melanoma.  
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CHAPTER 5: Materials and Methods
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Chemicals and antibodies.   Tamoxifen, fulvestrant, methyl succinate, STO609, oleic 
acid-BSA were purchased from Sigma Aldrich. The following rabbit polyclonal Antibodies 
were obtained from Cell Signaling: AMPKα, AMPKα1, phos-AMPKα, LKB1, phos-ACC, 
ACC, Phos-p70s6K, phos-s6, phos-4EBP1, cleaved PARP, cleaved caspase 3, and 
LC3B. ERα antibody purchased from Genetex. AMPKα2 antibody purchased from 
Millipore. siRNA against PRKAA2, LKB1 and CaMKK2 was purchased from Dharmacon. 
 
Cell culture. Cell lines were cultured in Dulbecco’s modified eagles medium (DMEM) 
supplemented with 10% FBS, 1% penicillin/streptomycin, and HEPES at 37°C humidified 
5% CO2 atmosphere. MCF7, MDA-MB-231 and 4175 cell lines were a gift from Andy 
Minn. LCC1 cells were a gift from Robert Clarke.  WM9 and 1205Lu cells were a gift 
from Meenhard Herlyn (Wistar Institute). Cell lines were authenticated through genetic 
testing by ATCC.  
 
Oxygen consumption measurements. Oxygen consumption was measured using a 
YSI 5300a Biological oxygen monitor.  Electrodes were equilibrated in media for 10 
minutes. Cells were trypsinized and suspended at 2x107cells per mL and injected into 
the chamber at a 1:10 dilution. After oxygen consumption rate was recorded, drug was 
injected into the chambers at 10 µM increments, allowing consumption rate to be 
determined after each injection.  Total protein per chamber was quantified by Lowry 
assay.  
 
Isolation of liver mitochondria. The liver was removed from a sacrificed mouse and 
homogenized in 8 volumes of sucrose buffer (0.25 M sucrose, 0.02 M KCl, 0.005 M 
MgCl2, 0.01 M KH2PO4 ( pH= 7.4). The homogenate was spun at 600 x g for 5 min at 
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4°C. The supernatant was then transferred to a new tube and centrifugation was 
repeated. Cleared supernatant was spun at 9000 x g for 10 min at 0°C and the pellet 
was resuspended in sucrose buffer. The following conditions were used for respiration 
measurements: Complex 1 respiration:  Sucrose buffer + 0.1 mM ADP, 5 mM glutamate 
and 5 mM malate. Complex 2 respiration: Sucrose buffer + 0.1 mM ADP and 5 mM 
sodium succinate. 
 
Respiration of permeabilized cells. BC cells were trypsinized and washed once with 
sucrose buffer. Cells were diluted to 2x106 cells per mL in sucrose buffer and digitonin 
was added at 25ug/mL and incubated at room temperature for  2 minutes, 
Permeabilization was confirmed with trypan blue stain.  Oxygen consumption 
measurements were performed as described for liver mitochondria.  
 
Cell survival assays. Modified MTT assay: Cells were plated in a 24 well plate at 5x104 
cells per well and allowed to attach overnight. After drug incubation, cells were washed, 
re-fed with fresh media and grown for 5-7 days until control cells reached confluency. An 
MTT assay kit (Roche) was used to measure survival and proliferation following the 
manufacturer’s instructions. Clonogenic survival assay: Cells were plated at 80% 
confluency in 60mm dishes and allowed to adhere overnight. Cells were treated with 
experimental conditions, trypsinized, washed, re-plated at low density (100-1000 cells) 
and incubated until visible colonies grew from single cells. Colonies stained with crystal 
violet and counted. Survival was reported as fraction of colony count over number of 
cells plated, normalized to control conditions. 
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Immunoblot analysis. Cells were lysed using nonident p-40 buffer (1% NP-40, 1 mM 
phenylmethylsulfonyl fluoride, 1X Complete Mini protease inhibitor cocktail [Roche], 1X 
phosphatase inhibitor cocktail 2 [Sigma] in PBS.) Protein concentrations of lysates were 
determined using DC protein assay (BioRad). Equal amounts of protein were resolved 
on sodium dodecyl sulfate polyacrylamide gels and transferred to polyvinylidene fluoride 
membranes. Membranes were blocked with 5% non-fat dried milk in TBS-T (20 mM Tris, 
137 mM NaCl, 0.1% Tween-20; pH 7.6) and then incubated in primary antibody followed 
by secondary antibody.  Proteins were visualized by incubating membranes in ECL 
chemicals and exposing to film. 
 
Generation of CRISPR-Cas9 knockout cell lines. Knock out cell lines were generated 
using the CRISPR-cas9 system as previously described104. sgRNAs were designed to 
target the first exon of the genes of interest using the CRISPR design tool at 
http://crispr.mit.edu/. Two sgRNA sequences were chosen for each gene of interest (See 
table below).  Briefly, sgRNA’s were cloned into CRISPR-cas9 plasmid. pSpCas9(BB)-
2A-Puro (PX459) was a gift from Feng Zhang (Addgene plasmid # 48139) . Cells were 
transfected using lipofectamine 2000 and carrier DNA. Media was changed 24hrs after 
transfection and cells were selected with puromycin for 48 hrs. Remaining cells grown 
up and clones were selected. Clones were screened for gene excision or mutation by 
DNA gel and expression of the protein of interested by western blot. Knock out was 
successful using both PRKAA1 sgRNAs 1 and 2. Knock out of ESR1 expression 
required combined transfection of sgRNA 1 and 2.  
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HPLC quantification of AMP and ATP. AMP and ATP quantified using a previously 
published method 105.  Briefly, 2-4x106 cells were plated in 10cm2 dishes and treated with 
tamoxifen. Cells were then pelleted and nucleotides extracted with perchloric acid. 
Extracts were analyzed by ion pair reverse phase HPLC. Analysis was carried out on a 
Jasco HPLC. Separation was performed on SUPELCOSIL C18 column (15 cm x 4.6 
mm, 3 µm particle size) in combination with a Supelguard Acentis C18 guard column (2 
cm x 4.0 mm) from Sigma.  
 
LC-MS/MS metabolite analysis. Liquid chromatography-selected reaction monitoring 
(LC-SRM)/MS was used for analysis of acyl-CoA thioesters. Methods were previously 
described in detail106.  CoAs were separated using a reversed-phase HPLC 
Phenomenex Luna C18 column (2.0 mm × 150 mm, particle size 3.5 μm) with 5 mM 
ammonium acetate in water as solvent A, 5 mM ammonium acetate in ACN/water (95:5; 
v/v) as solvent B, and ACN/water/formic acid (80:20:0.1; v/v/v) as solvent C. Samples 
were analyzed using an API 4000 triple-quadrupole mass spectrometer (Applied 
Biosystems, Foster City, CA) in the positive electrospray (ESI) mode. Samples (10 μL) 
Table V-1: sequences of sgRNA for CRISPR-cas9 knock out cell lines 
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were injected using a Leap CTC autosampler (CTC Analytics, Switzerland) where they 
were maintained at 4 °C.   
 
Short-chain and Long-chain acyl-CoA extraction. Short-chain acyl-CoA extraction. 
Extractions were performed as described in detail previously106. Briefly, cells were lifted 
manually with a cell scraper, centrifuged at 500 x g for 5 min and resuspended in 1 mL 
of ice-cold 10% TCA and pulse-sonicated for 30 s on ice using a sonic dismembranator 
(Fisher), followed by a 5 min centrifugation at 15,000 x g. The supernatant was 
transferred to a fresh tube, and the pellet was discarded. The supernatant was purified 
by solid-phase extraction as follows: Oasis HLB 1 cm3 (30 mg) SPE columns (Waters) 
were conditioned with 1 mL of methanol followed by 1 mL of water. The collected 
supernatant was applied, washed with 1 mL of water, and finally eluted using three 
subsequent applications of 0.5 mL of methanol containing 25 mM ammonium acetate. 
Eluted compounds were dried down under nitrogen and resuspended in 100 μL of 5% 5-
SSA. For isotopologue analysis, the same extraction was used, except that no internal 
standard was added. Long-chain acyl-CoAs extraction- Extractions were performed as 
described in detail previously107. Cells were lifted manually with a cell scraper, 
centrifuged at 500 x g for 5 min and resuspended in 550 µL/10 cm2 plate of ACN:IPA 
(3:1; v/v).  The internal standard prepared using stable isotope labeling by essential 
nutrients in cell culture (SILEC) was added (200 µL) and samples were pulse sonicated 
with a probe tip sonicator on ice 30 times for 0.5 s.  250 µL of 100 mM KH2PO4 (pH 6.7) 
was added to the samples, then vortex-mixed and spun down for 10 min at 16,000 x g at 
4°C.  The supernatant was transferred to a glass tube and acidified with 125 µL of 
glacial acetic acid.  SPE columns were equilibrated with 1 mL of ACN/IPA/water/acetic 
acid (9:3:4:4; v/v/v/v) washing solvent.  Samples were transferred to the columns, which 
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were washed two times with 1 mL of the washing solvent.  The acyl-CoAs were then 
eluted by washing the columns twice with 500 µL methanol/250 mM ammonium formate 
(4:1; v/v) into glass tubes.  After evaporation to dryness under nitrogen gas, the eluates 
were re-dissolved in 50 µL of water/ACN (7:3; v/v) containing 5 % SSA (w/v) and 
transferred to HPLC vials for LC-SRM/MS analysis.   
 
Lactate extraction and analysis by LC-MS/MS: Media was aspirated and cells were 
quenched by the direct addition of 1 mL -80 °C 4:1 methanol:water (v/v) to the cell 
culture dish. Plates were placed at -80 °C for 20 min then scraped and transferred into 
Eppendorf tubes. Samples were pulse sonicated on ice for 30 sec at a rate of 1 
pulse/sec prior to centrifugation at 16,000 x g at 4 oC for 10 min. The supernatants were 
then transferred to clean glass tubes and evaporated to dryness under nitrogen. Dried 
residues were resuspended in 100 µL of mobile phase A for LC-MS analysis. For 
labeling studies cells were grown in media omitting glucose supplemented with 1 mg/mL 
[13C6]-glucose. Details of the LC-MS/MS analysis have been describes in detail 
previously 108. 
 
Quantification of tamoxifen and metabolites in tumor tissue. Tumor was removed 
from mouse under anesthesia and flash frozen in liquid N2. Frozen tissue was weighed 
and homogenized by electric homogenizer on ice in 4:1 methanol:water (v/v). Samples 
were then centrifuged at 16,000 x g at 4 oC for 10 min. 10 µL of the resulting supernatant 
was analyzed by reverse phase LC-MS/MS utilizing teniposide as the internal standard 
for absolute quantification. 
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siRNA transfection. Cells were grown in 60 mm dishes to approximately 60% 
confluency. The cells were transfected with lipofectamine RNAi Max and siRNA to 
PRKAA2 at 50 nM mixed in OptiMEM. Transfection mixture was added to the cell culture 
plates in complete DMEM and incubated for 24 hrs before the plates were washed and 
refed with fresh complete DMEM.  Cells were cultured for an additional 48 hrs before 
treatment with tamoxifen.  
 
BODIPY 493/503 staining. BODIPY 493/503 was purchased from Molecular Probes. 
Staining solution was made up at 2 μg/mL in PBS. After drug treatments, cells were fixed 
using 4% paraformaldehyde and stored at 4°C. Neutral lipid staining was performed by 
pelleting the cells and re-suspending in staining solution and incubated for 10 mins at 
room temperature. Cells were washed 2x with PBS, suspended in 500 µL PBS and 
strained. Cells were analyzed for mean BODIPY stain intensity by flow cytometry (FL1-
H). 
 
[14C] acetate labeling of lipid pools: The protocol has been previously described109. 
Briefly, tamoxifen or vehicle treated ells were incubated with [14C]acetate for 2 hours. 
The cells were then washed with PBS/EDTA and trypsinized. Pellets were washed twice 
with PBS, and fatty acids were extracted with chloroform-methanol (1:1) for 30 min. The 
extract was dried under N2 and then extracted with water-saturated butanol. Butanol was 
evaporated under N2, and labeled fatty acids were detected by scintillation counting 
 
[35S] labeling. Cells were plated in 60 mm dish and treated for experimental conditions. 
Cells were incubated with methionine/cysteine free media for 30 min. Hot labeling media 
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was made up at 0.075 mCi/mL [35S]-methionine/cysteine. Cells were incubated with 
labeling media for 30 mins. Cells were washed with cold PBS and harvested for protein. 
Protein assay performed on cold samples and equal amounts of [35S] labeled protein 
were resolved on sodium dodecyl sulfate polyacrylamide gels. Gel was washed with 
fixing solution (water with 20% methanol, 10% acetic acid) for 30 min, washed with DI 
water, then washed with enlightening solution (PerkinElmer) for 30 min. Gel was dried 
overnight using a BioRad gel drying apparatus. The gel was exposed to autoradiography 
film at -80°C and film was developed. 
 
Orthotopic xenograft tumors: Four-week old female nu/nu mice were purchased from 
Charles River Laboratories and housed in the University of Pennsylvania animal facility 
maintained on a 12 h light/dark cycle and given free access to water and food ad libitum. 
2x106 4175 cells suspended in 50 µL of a 50/50 mixture of PBS and Matrigel Matrix 
basement membrane (Corning) were injected into the mammary fat pad.  Tumor growth 
was measured twice weekly by calipers. Tumor volume was calculated by the modified 
ellipsoid formula: Tumor volume= 1/2(length × width2)110. All animal experiments were 
performed in accordance with the “Guide for the Care and Use of Laboratory Animals” of 
the National Research Council of the National Academies and approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee. 
 
In vivo Tamoxifen and 3BP treatment.  Tamoxifen was dissolved 20 mg in 200 µL 
ethanol and 800 µL peanut oil. Ethanol was evaporated off overnight. 3BP was dissolved 
at 0.5 mg/mL in sterile PBS immediately before injection. Mice were dosed via 
intraperitoneal injection.  
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Protein analysis from tumors. Tumors were removed under isoflurane anesthesia and 
the animals immediately sacrificed. Tumors were flash frozen in liquid N2.  Lysis buffer 
was 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA. Immediately 
before use PMSF, complete mini, and phosphatase inhibitor cocktail was added. On dry 
ice, the tumor was cut and random pieces from different sections of the tumor were 
weighed and added to lysis buffer at 40mg/mL. The tumor was homogenized by electric 
homogenizer on ice. 1% Triton-X was then added and the lysate sonicated. Samples 
were then set on ice for 10 minutes then spun at 12000 rpm and 4°C for 10 min and the 
pellet discarded.  
 
Statistical analysis: All statistical analyses were performed using a two-tailed Student’s 
t test assuming homoscedasticity. A p value < 0.05 was considered statistically 
significant. 
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